Literature DB >> 16947080

Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.

Pravat K Mandal1, Jay W Pettegrew, Eliezer Masliah, Ronald L Hamilton, Ratna Mandal.   

Abstract

Amyloidogenic proteins (Abeta peptide) in Alzheimer's disease (AD) and alpha-synuclein (alpha-Syn) in Parkinson's disease (PD) are typically soluble monomeric precursors, which undergo remarkable conformational changes and culminate in the form of aggregates in diseased condition. Overlap of clinical and neuropathological features of both AD and PD are observed in dementia with Lewy body (DLB) disease, the second most common form of dementia after AD. The identification of a 35-amino acid fragment of alpha-Syn in the amyloid plaques in DLB brain have raised the possibility that Abeta and alpha-Syn interact with each other. In this report, the molecular interaction of alpha-Syn with Abeta40 and/or Abeta42 are investigated using multidimensional NMR spectroscopy. NMR data in the membrane mimic environment indicate specific sites of interaction between membrane-bound alpha-Syn with Abeta peptide and vice versa. These Abeta-alpha-Syn interactions are demonstrated by reduced amide peak intensity or change in chemical shift of amide proton of the interacting proteins. Based on NMR results, the plausible molecular mechanism of overlapping pathocascade of AD and PD in DLB due to interactions between alpha-Syn and Abeta is described. To the best of our knowledge, it is the first report using multidimensional NMR spectroscopy that elucidates molecular interactions between Abeta and alpha-Syn which may lead to onset of DLB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16947080     DOI: 10.1007/s11064-006-9140-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  44 in total

1.  A common sense approach to peak picking in two-, three-, and four-dimensional spectra using automatic computer analysis of contour diagrams. 1991.

Authors:  Daniel S Garrett; Robert Powers; Angela M Gronenborn; G Marius Clore
Journal:  J Magn Reson       Date:  2011-12       Impact factor: 2.229

2.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

3.  NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases.

Authors:  Osamu Yokota; Seishi Terada; Hideki Ishizu; Hiroshi Ujike; Takeshi Ishihara; Hanae Nakashima; Minoru Yasuda; Yoshihiro Kitamura; Kenji Uéda; Frédéric Checler; Shigetoshi Kuroda
Journal:  Acta Neuropathol       Date:  2002-08-14       Impact factor: 17.088

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Cortical Lewy body dementia: clinical features and classification.

Authors:  W R Gibb; P J Luthert; I Janota; P L Lantos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

6.  Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins.

Authors:  D Marion; K Wüthrich
Journal:  Biochem Biophys Res Commun       Date:  1983-06-29       Impact factor: 3.575

7.  A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.

Authors:  Chang-Wei Liu; Benoit I Giasson; Karen A Lewis; Virginia M Lee; George N Demartino; Philip J Thomas
Journal:  J Biol Chem       Date:  2005-04-19       Impact factor: 5.157

8.  Alzheimer's disease: soluble oligomeric Abeta(1-40) peptide in membrane mimic environment from solution NMR and circular dichroism studies.

Authors:  Pravat K Mandal; Jay W Pettegrew
Journal:  Neurochem Res       Date:  2004-12       Impact factor: 3.996

9.  Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.

Authors:  He-Jin Lee; Chan Choi; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2001-10-25       Impact factor: 5.157

10.  Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease.

Authors:  H Shao; S Jao; K Ma; M G Zagorski
Journal:  J Mol Biol       Date:  1999-01-15       Impact factor: 5.469

View more
  86 in total

1.  Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein.

Authors:  Judit Oláh; Orsolya Vincze; Dezsõ Virók; Dóra Simon; Zsolt Bozsó; Natália Tõkési; István Horváth; Emma Hlavanda; János Kovács; Anna Magyar; Mária Szũcs; Ferenc Orosz; Botond Penke; Judit Ovádi
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

2.  Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.

Authors:  Lani K Clinton; Mathew Blurton-Jones; Kristoffer Myczek; John Q Trojanowski; Frank M LaFerla
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Presenilin-2 gene mutation presenting as Lewy body dementia?

Authors:  Loredana Raciti; Alessandra Nicoletti; Francesco Le Pira; Virginia Andreoli; Donatella Contrafatto; Salvatore Lanzafame; Tiziana Maci; Antonio Gambardella; Aldo Quattrone; Mario Zappia
Journal:  Neurol Sci       Date:  2011-03-16       Impact factor: 3.307

4.  α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects.

Authors:  Simona Daniele; Deborah Pietrobono; Jonathan Fusi; Caterina Iofrida; Lucia Chico; Lucia Petrozzi; Annalisa Lo Gerfo; Filippo Baldacci; Fabio Galetta; Gabriele Siciliano; Ubaldo Bonuccelli; Gino Santoro; Maria Letizia Trincavelli; Ferdinando Franzoni; Claudia Martini
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 5.  Cross-interactions between the Alzheimer Disease Amyloid-β Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis.

Authors:  Jinghui Luo; Sebastian K T S Wärmländer; Astrid Gräslund; Jan Pieter Abrahams
Journal:  J Biol Chem       Date:  2016-06-20       Impact factor: 5.157

6.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

Review 7.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

8.  Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Authors:  Leslie Crews; Brian Spencer; Paula Desplats; Christina Patrick; Amy Paulino; Edward Rockenstein; Lawrence Hansen; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

9.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.